1. Home
  2. HTFL vs TRVI Comparison

HTFL vs TRVI Comparison

Compare HTFL & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Heartflow Inc.

HTFL

Heartflow Inc.

N/A

Current Price

$57.56

Market Cap

2.2B

Sector

N/A

ML Signal

N/A

Logo Trevi Therapeutics Inc.

TRVI

Trevi Therapeutics Inc.

N/A

Current Price

$13.41

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HTFL
TRVI
Founded
2007
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
2025
2019

Fundamental Metrics

Financial Performance
Metric
HTFL
TRVI
Price
$57.56
$13.41
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
9
11
Target Price
★ $50.50
$28.18
AVG Volume (30 Days)
1.3M
★ 2.5M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 82.37
31.91
EPS
N/A
★ N/A
Revenue
★ $176,034,000.00
N/A
Revenue This Year
$41.24
N/A
Revenue Next Year
$24.11
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 39.92
N/A
52 Week Low
$20.13
$9.82
52 Week High
$57.74
$20.22

Technical Indicators

Market Signals
Indicator
HTFL
TRVI
Relative Strength Index (RSI) 69.75 47.88
Support Level $46.46 $13.08
Resistance Level N/A $13.55
Average True Range (ATR) 2.89 0.67
MACD 0.64 0.18
Stochastic Oscillator 90.75 92.05

Price Performance

Historical Comparison
HTFL
TRVI

About HTFL Heartflow Inc.

HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.

About TRVI Trevi Therapeutics Inc.

Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.

Share on Social Networks: